TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. Tonix reported Q2 2026 Tonmaya net sales of approximately $11 million (up 197% QoQ) with expanded payer coverage reaching about 136 million lives, while advancing its TNX-102 SL MDD Phase 2 (first patient enrolled) and keeping the TNX-4800 Lyme Phase 2 on track for Q1 2027 start. Cash of $176.2 million plus subsequent equity proceeds funds operations only into early Q2 2027, and SG&A/R&D roughly doubled YoY as the company ramps the launch and pipeline.
- + Tonmaya Q2 net sales ~$11M, up 197% QoQ (nearly tripled)
- + Strong launch KPIs: 12,592 total Rx (+100%), new patients +36%, refills +207% QoQ
- + Tonmaya coverage expanded to ~136M lives (~43% of U.S.) with GPO deals covering ~52M lives and a managed Medicare deal adding ~9M lives on Jan 1, 2027
- + TNX-4800 Lyme prevention Phase 2 adaptive field study on track to start Q1 2027 after positive FDA Type C minutes
- − Cash runway only into early Q2 2027, with cash declining from ~$207.6M to ~$176.2M
- − R&D expense roughly doubled YoY to ~$19.4M
- − SG&A expense roughly doubled YoY to ~$36.0M as launch costs ramp
- − Net loss widened to ~$40.6M (~$2.44/share) from ~$28.3M YoY
- − Gross-to-net for Tonmaya expected to continue fluctuating in Q3/Q4
- − TNX-4800 Phase 2 enrollment could extend into 2029 if Lyme attack rate is lower than planned
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| TONMYA net sales | $11M | Q2 2026 | — |
| Total covered lives for TONMYA across commercial, managed Medicare, and Medicaid | 136M | Q2 2026 | — |
| Total prescriptions | 12,592 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNXP
this stock
Tonix Pharmaceuticals Holding Corp.
|
$125.20M | -53.3% | +29.8% | — | 17.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNXP | -18.1% | -38.5% | -49.1% | -25.1% | -53.3% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -19.2% | -40.4% | -59.0% | -27.1% | -67.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.